The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Community Fast Track, 2003NBD Peptides in MPTP Pre-clinical Model
Understanding the mechanism of the disease process of Parkinson's dis and development of effective neuroprotective therapeutic approach to halt the disease progression are of paramount importance. It...
-
Community Fast Track, 2003Biomarker Discovery in Parkinson’s Disease
The primary goal of our studies is to expand our ongoing biomarker discovery program in order to establish biological markers of Parkinson's disease (PD). The imperative to develop effective therapies...
-
Community Fast Track, 2003Mitochondrial Trafficking in Dopaminergic Neuron Injury
Mitochondria are considered to be the "power house" of all cells, including neurons, because they convert food into energy in the form that cells can use. When mitochondria fail, cells typically die...
-
LEAPS, 2003High Resolution Whole Genome Study to Determine Genetic Loci of Parkinson's Disease
The Cox team will leverage Perlegen's high-density array technology and the Mayo Clinic's extensive patient database, clinical expertise and DNA bank to create a genetic map of causes and risk factors...
-
Specification, Patterning, and Maintenance of Midbrain Dopam, 2004Role of Nurr1 in survival, maintenance and function of midbrain dopamine neurons:Implications for disease intervention and therapy for PD
Nurr1 has been discovered as one of the key factors regulating survival and maintenance of midbrain dopamine neurons. Last year, Le and collaborators (Nature Genetics, 3:385, 2003) reported the...
-
Cell Line, 2002Development of a Stem Cell Replacement Therapy for Parkinson's Disease: Induction of Midbrain DA Neurons from ES Cells
In the present project three groups at the Karolinska Institute join forces in order to: 1) Identify molecular players capable of inducing a midbrain dopaminergic (DA) phenotype. We previously found...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.